Fenghuang Zhan
Concepts (592)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Myeloma | 139 | 2025 | 3049 | 10.260 |
Why?
| Gene Expression Regulation, Neoplastic | 53 | 2025 | 857 | 3.200 |
Why?
| Drug Resistance, Neoplasm | 25 | 2020 | 326 | 3.050 |
Why?
| Plasma Cells | 24 | 2025 | 239 | 2.940 |
Why?
| Gene Expression Profiling | 44 | 2025 | 1105 | 2.810 |
Why?
| Monoclonal Gammopathy of Undetermined Significance | 9 | 2025 | 125 | 2.690 |
Why?
| Cell Proliferation | 25 | 2022 | 1023 | 2.130 |
Why?
| Antineoplastic Agents | 29 | 2020 | 1222 | 2.030 |
Why?
| Cell Line, Tumor | 46 | 2025 | 1470 | 1.890 |
Why?
| Neoplastic Stem Cells | 7 | 2020 | 99 | 1.620 |
Why?
| Pyrazines | 19 | 2023 | 190 | 1.520 |
Why?
| Disease Progression | 19 | 2025 | 871 | 1.520 |
Why?
| Mice | 48 | 2025 | 5949 | 1.400 |
Why?
| Paraproteinemias | 9 | 2024 | 74 | 1.390 |
Why?
| Humans | 161 | 2025 | 52483 | 1.380 |
Why?
| Lymphoma, B-Cell | 5 | 2021 | 61 | 1.370 |
Why?
| Apoptosis | 18 | 2025 | 1119 | 1.360 |
Why?
| Prognosis | 39 | 2025 | 2099 | 1.320 |
Why?
| Boronic Acids | 17 | 2014 | 183 | 1.320 |
Why?
| Bone Resorption | 6 | 2024 | 302 | 1.320 |
Why?
| Animals | 59 | 2025 | 13505 | 1.210 |
Why?
| Tumor Microenvironment | 6 | 2024 | 256 | 1.200 |
Why?
| Neoplasm Proteins | 7 | 2021 | 334 | 1.140 |
Why?
| Osteolysis | 4 | 2022 | 75 | 1.080 |
Why?
| B-Lymphocytes | 8 | 2021 | 184 | 1.040 |
Why?
| Cell Cycle Proteins | 4 | 2023 | 169 | 1.000 |
Why?
| T-Lymphocytes | 8 | 2024 | 340 | 0.960 |
Why?
| Hematopoietic Stem Cell Transplantation | 6 | 2024 | 603 | 0.940 |
Why?
| Ubiquitination | 3 | 2021 | 47 | 0.910 |
Why?
| Proteasome Inhibitors | 7 | 2020 | 104 | 0.890 |
Why?
| Signal Transduction | 21 | 2023 | 1671 | 0.850 |
Why?
| Proteasome Endopeptidase Complex | 4 | 2018 | 117 | 0.800 |
Why?
| MicroRNAs | 7 | 2022 | 387 | 0.780 |
Why?
| Antigens, CD | 8 | 2024 | 218 | 0.740 |
Why?
| Neoplasms | 3 | 2024 | 1325 | 0.710 |
Why?
| Iron | 3 | 2017 | 127 | 0.690 |
Why?
| Ascorbic Acid | 2 | 2017 | 25 | 0.680 |
Why?
| Carrier Proteins | 3 | 2017 | 313 | 0.650 |
Why?
| CDC2-CDC28 Kinases | 3 | 2015 | 11 | 0.640 |
Why?
| Cation Transport Proteins | 2 | 2019 | 27 | 0.630 |
Why?
| Chromosome Aberrations | 7 | 2025 | 297 | 0.630 |
Why?
| Up-Regulation | 6 | 2020 | 454 | 0.610 |
Why?
| Ubiquitins | 2 | 2016 | 40 | 0.610 |
Why?
| Cyclin-Dependent Kinases | 2 | 2010 | 26 | 0.600 |
Why?
| Mice, Inbred NOD | 5 | 2020 | 92 | 0.600 |
Why?
| Oligonucleotide Array Sequence Analysis | 19 | 2014 | 405 | 0.600 |
Why?
| Glycolysis | 3 | 2022 | 73 | 0.600 |
Why?
| Waldenstrom Macroglobulinemia | 1 | 2018 | 40 | 0.590 |
Why?
| Cell Survival | 11 | 2020 | 612 | 0.580 |
Why?
| Cell Differentiation | 9 | 2023 | 665 | 0.570 |
Why?
| Proto-Oncogene Proteins c-akt | 5 | 2023 | 169 | 0.570 |
Why?
| Pyrimidines | 3 | 2015 | 199 | 0.560 |
Why?
| STAT3 Transcription Factor | 4 | 2016 | 85 | 0.550 |
Why?
| Killer Cells, Natural | 5 | 2024 | 116 | 0.540 |
Why?
| Pyruvate Kinase | 1 | 2017 | 7 | 0.540 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 1031 | 0.530 |
Why?
| RNA Splicing | 1 | 2017 | 41 | 0.530 |
Why?
| Female | 46 | 2025 | 28171 | 0.500 |
Why?
| Protein-Tyrosine Kinases | 2 | 2015 | 87 | 0.500 |
Why?
| Down-Regulation | 9 | 2019 | 346 | 0.490 |
Why?
| Cyclopentanes | 1 | 2015 | 12 | 0.490 |
Why?
| Male | 36 | 2025 | 26761 | 0.480 |
Why?
| Transplantation, Autologous | 5 | 2024 | 488 | 0.480 |
Why?
| Thalidomide | 10 | 2023 | 377 | 0.480 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2015 | 68 | 0.480 |
Why?
| Aldehyde Dehydrogenase | 1 | 2014 | 25 | 0.470 |
Why?
| Osteoclasts | 7 | 2023 | 428 | 0.460 |
Why?
| Dexamethasone | 7 | 2024 | 438 | 0.450 |
Why?
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2020 | 17 | 0.450 |
Why?
| Models, Biological | 5 | 2018 | 735 | 0.420 |
Why?
| Receptors, Retinoic Acid | 2 | 2013 | 22 | 0.420 |
Why?
| Hematologic Neoplasms | 1 | 2015 | 106 | 0.420 |
Why?
| Cystatin M | 2 | 2024 | 19 | 0.420 |
Why?
| RNA, Messenger | 13 | 2021 | 1132 | 0.410 |
Why?
| Flow Cytometry | 8 | 2018 | 478 | 0.400 |
Why?
| B-Cell Maturation Antigen | 2 | 2024 | 98 | 0.400 |
Why?
| Antigens, Neoplasm | 6 | 2014 | 147 | 0.400 |
Why?
| Mice, Transgenic | 7 | 2021 | 552 | 0.400 |
Why?
| Glucuronidase | 4 | 2018 | 47 | 0.390 |
Why?
| Aged | 26 | 2025 | 10121 | 0.390 |
Why?
| Predictive Value of Tests | 5 | 2016 | 944 | 0.370 |
Why?
| Antibodies, Bispecific | 2 | 2023 | 94 | 0.360 |
Why?
| Syndecan-1 | 6 | 2017 | 74 | 0.360 |
Why?
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 6 | 0.360 |
Why?
| Arsenicals | 1 | 2010 | 15 | 0.350 |
Why?
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 20 | 0.350 |
Why?
| Oxides | 1 | 2010 | 21 | 0.350 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 12 | 2015 | 582 | 0.340 |
Why?
| Janus Kinase 1 | 1 | 2010 | 16 | 0.340 |
Why?
| Proto-Oncogene Proteins c-jun | 2 | 2009 | 75 | 0.340 |
Why?
| MAP Kinase Kinase 1 | 1 | 2010 | 23 | 0.340 |
Why?
| Middle Aged | 25 | 2025 | 13028 | 0.330 |
Why?
| DNA-Binding Proteins | 4 | 2021 | 422 | 0.330 |
Why?
| Immunotherapy, Adoptive | 2 | 2024 | 166 | 0.330 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 82 | 0.330 |
Why?
| Early Growth Response Protein 1 | 1 | 2009 | 34 | 0.320 |
Why?
| Transcription Factors | 6 | 2022 | 566 | 0.320 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 2 | 2024 | 106 | 0.310 |
Why?
| Tretinoin | 1 | 2009 | 54 | 0.310 |
Why?
| Oligopeptides | 3 | 2015 | 92 | 0.310 |
Why?
| Membrane Proteins | 4 | 2018 | 335 | 0.300 |
Why?
| Xenograft Model Antitumor Assays | 7 | 2019 | 220 | 0.300 |
Why?
| Osteogenesis | 5 | 2023 | 366 | 0.300 |
Why?
| NF-kappa B | 3 | 2018 | 322 | 0.300 |
Why?
| Genes, Neoplasm | 1 | 2008 | 31 | 0.290 |
Why?
| Tumor Cells, Cultured | 6 | 2020 | 460 | 0.290 |
Why?
| Antibodies | 3 | 2024 | 159 | 0.290 |
Why?
| Microarray Analysis | 3 | 2018 | 71 | 0.280 |
Why?
| Adult | 22 | 2025 | 14161 | 0.280 |
Why?
| Chromosomes, Human, Pair 1 | 4 | 2023 | 96 | 0.280 |
Why?
| Oxidative Stress | 5 | 2017 | 807 | 0.280 |
Why?
| Immunologic Factors | 5 | 2015 | 117 | 0.270 |
Why?
| S-Phase Kinase-Associated Proteins | 1 | 2007 | 2 | 0.270 |
Why?
| Interleukin-6 | 3 | 2019 | 278 | 0.270 |
Why?
| Neoplasms, Plasma Cell | 2 | 2023 | 37 | 0.270 |
Why?
| Retrospective Studies | 8 | 2025 | 6607 | 0.270 |
Why?
| Tumor Suppressor Protein p53 | 2 | 2008 | 221 | 0.270 |
Why?
| Small Molecule Libraries | 2 | 2019 | 67 | 0.270 |
Why?
| Pyrazoles | 2 | 2020 | 114 | 0.260 |
Why?
| Aged, 80 and over | 8 | 2025 | 3392 | 0.260 |
Why?
| Mice, SCID | 9 | 2018 | 182 | 0.250 |
Why?
| CD8-Positive T-Lymphocytes | 3 | 2024 | 132 | 0.250 |
Why?
| Endopeptidase Clp | 1 | 2025 | 2 | 0.240 |
Why?
| Protein Kinase Inhibitors | 3 | 2024 | 227 | 0.240 |
Why?
| Genomics | 2 | 2023 | 268 | 0.240 |
Why?
| Risk Factors | 11 | 2018 | 3889 | 0.240 |
Why?
| Survival Rate | 8 | 2020 | 945 | 0.230 |
Why?
| Enzyme Inhibitors | 4 | 2019 | 372 | 0.230 |
Why?
| Bone Diseases | 4 | 2016 | 96 | 0.230 |
Why?
| Bone Marrow | 7 | 2024 | 364 | 0.230 |
Why?
| Polycomb Repressive Complex 2 | 2 | 2021 | 48 | 0.230 |
Why?
| ROC Curve | 1 | 2025 | 253 | 0.230 |
Why?
| Diffusion Magnetic Resonance Imaging | 1 | 2025 | 133 | 0.230 |
Why?
| Single-Cell Analysis | 1 | 2025 | 81 | 0.220 |
Why?
| Receptors, LDL | 1 | 2024 | 71 | 0.220 |
Why?
| Transcriptome | 2 | 2025 | 370 | 0.220 |
Why?
| Propionates | 1 | 2024 | 24 | 0.220 |
Why?
| Hydroxybenzoates | 1 | 2024 | 24 | 0.220 |
Why?
| TNF Receptor-Associated Factor 3 | 2 | 2022 | 13 | 0.220 |
Why?
| Ferritins | 1 | 2024 | 36 | 0.220 |
Why?
| Myeloid Progenitor Cells | 1 | 2023 | 17 | 0.220 |
Why?
| X-Ray Microtomography | 1 | 2024 | 79 | 0.220 |
Why?
| Histocompatibility Antigens Class I | 2 | 2015 | 48 | 0.210 |
Why?
| Melphalan | 3 | 2023 | 181 | 0.210 |
Why?
| Cholesterol | 1 | 2024 | 153 | 0.210 |
Why?
| Antigens, CD19 | 3 | 2018 | 28 | 0.210 |
Why?
| Bone Marrow Cells | 4 | 2015 | 190 | 0.210 |
Why?
| Neoplasms, Second Primary | 1 | 2024 | 77 | 0.210 |
Why?
| Proteolysis | 4 | 2018 | 101 | 0.210 |
Why?
| Membrane Glycoproteins | 6 | 2009 | 244 | 0.210 |
Why?
| Positron-Emission Tomography | 1 | 2025 | 301 | 0.210 |
Why?
| Cell Transformation, Neoplastic | 1 | 2024 | 184 | 0.210 |
Why?
| Genes, myc | 3 | 2019 | 39 | 0.210 |
Why?
| Intercellular Signaling Peptides and Proteins | 4 | 2007 | 105 | 0.210 |
Why?
| Proto-Oncogene Proteins c-myc | 3 | 2025 | 53 | 0.210 |
Why?
| Lymphoma | 1 | 2024 | 71 | 0.210 |
Why?
| Bone Diseases, Metabolic | 1 | 2024 | 78 | 0.210 |
Why?
| Colonic Neoplasms | 2 | 2022 | 163 | 0.210 |
Why?
| Homeostasis | 1 | 2024 | 201 | 0.210 |
Why?
| Cluster Analysis | 5 | 2009 | 233 | 0.200 |
Why?
| Gene Knockdown Techniques | 3 | 2018 | 108 | 0.200 |
Why?
| Phenols | 1 | 2024 | 92 | 0.200 |
Why?
| Bone and Bones | 2 | 2021 | 494 | 0.200 |
Why?
| NM23 Nucleoside Diphosphate Kinases | 1 | 2022 | 4 | 0.200 |
Why?
| Protein Binding | 2 | 2018 | 667 | 0.200 |
Why?
| Neutropenia | 1 | 2023 | 115 | 0.200 |
Why?
| Recurrence | 7 | 2018 | 672 | 0.200 |
Why?
| Periodontitis | 1 | 2022 | 11 | 0.200 |
Why?
| Randomized Controlled Trials as Topic | 6 | 2016 | 595 | 0.200 |
Why?
| Antibodies, Monoclonal | 3 | 2013 | 481 | 0.190 |
Why?
| In Situ Hybridization, Fluorescence | 5 | 2023 | 263 | 0.190 |
Why?
| Case-Control Studies | 8 | 2020 | 1201 | 0.190 |
Why?
| Reactive Oxygen Species | 4 | 2017 | 421 | 0.190 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 170 | 0.190 |
Why?
| Protein Stability | 2 | 2020 | 45 | 0.190 |
Why?
| Osteoporosis | 1 | 2023 | 162 | 0.190 |
Why?
| Kaplan-Meier Estimate | 5 | 2016 | 483 | 0.190 |
Why?
| Arthritis, Rheumatoid | 1 | 2022 | 116 | 0.180 |
Why?
| Mitochondria | 1 | 2025 | 430 | 0.180 |
Why?
| Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 1 | 2021 | 1 | 0.180 |
Why?
| Nuclear Factor 90 Proteins | 1 | 2021 | 1 | 0.180 |
Why?
| RANK Ligand | 1 | 2022 | 187 | 0.180 |
Why?
| Ubiquitin-Protein Ligases | 2 | 2020 | 96 | 0.180 |
Why?
| Gene Expression Regulation | 3 | 2022 | 990 | 0.180 |
Why?
| Venous Thromboembolism | 3 | 2011 | 77 | 0.180 |
Why?
| Phenylpropionates | 1 | 2021 | 13 | 0.180 |
Why?
| Hippurates | 1 | 2021 | 10 | 0.180 |
Why?
| Gene Expression | 4 | 2017 | 618 | 0.180 |
Why?
| Cell Cycle | 4 | 2010 | 230 | 0.180 |
Why?
| Bone Neoplasms | 2 | 2015 | 184 | 0.180 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 202 | 0.170 |
Why?
| Protease Inhibitors | 3 | 2011 | 61 | 0.170 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2021 | 56 | 0.170 |
Why?
| Antigens, CD20 | 2 | 2014 | 6 | 0.170 |
Why?
| Treatment Outcome | 12 | 2020 | 5422 | 0.170 |
Why?
| Cell Movement | 2 | 2015 | 268 | 0.170 |
Why?
| Neoplasm Metastasis | 4 | 2015 | 243 | 0.170 |
Why?
| Evolution, Molecular | 1 | 2021 | 93 | 0.170 |
Why?
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2015 | 59 | 0.170 |
Why?
| Time Factors | 8 | 2021 | 2968 | 0.170 |
Why?
| Disease-Free Survival | 7 | 2016 | 460 | 0.170 |
Why?
| Colorectal Neoplasms | 2 | 2022 | 294 | 0.170 |
Why?
| Chromosomal Instability | 3 | 2021 | 16 | 0.170 |
Why?
| Practice Guidelines as Topic | 1 | 2023 | 488 | 0.170 |
Why?
| Cytotoxicity, Immunologic | 4 | 2015 | 58 | 0.170 |
Why?
| Clinical Trials as Topic | 1 | 2022 | 467 | 0.160 |
Why?
| Tumor Suppressor Proteins | 2 | 2019 | 130 | 0.160 |
Why?
| Neoplasm Recurrence, Local | 1 | 2024 | 649 | 0.160 |
Why?
| DNA, Single-Stranded | 1 | 2020 | 88 | 0.160 |
Why?
| NF-E2-Related Factor 2 | 1 | 2019 | 47 | 0.160 |
Why?
| Oncogene Proteins | 1 | 2019 | 19 | 0.160 |
Why?
| Mitosis | 3 | 2015 | 88 | 0.160 |
Why?
| Excitation Contraction Coupling | 1 | 2018 | 3 | 0.150 |
Why?
| Carcinoma, Neuroendocrine | 1 | 2019 | 25 | 0.150 |
Why?
| Transplantation, Heterologous | 2 | 2017 | 79 | 0.150 |
Why?
| Receptors, Interleukin-6 | 1 | 2018 | 23 | 0.150 |
Why?
| rab GTP-Binding Proteins | 1 | 2019 | 36 | 0.150 |
Why?
| Cardiomegaly | 1 | 2018 | 38 | 0.150 |
Why?
| Healthcare Disparities | 1 | 2022 | 299 | 0.150 |
Why?
| Neovascularization, Pathologic | 3 | 2009 | 153 | 0.150 |
Why?
| Drug Tolerance | 1 | 2018 | 60 | 0.150 |
Why?
| Adaptation, Physiological | 2 | 2018 | 110 | 0.150 |
Why?
| Pyridines | 1 | 2019 | 132 | 0.150 |
Why?
| Blotting, Western | 3 | 2015 | 590 | 0.150 |
Why?
| Myocardial Contraction | 1 | 2018 | 112 | 0.150 |
Why?
| Ventricular Remodeling | 1 | 2018 | 64 | 0.150 |
Why?
| Cell Nucleus | 1 | 2018 | 187 | 0.140 |
Why?
| Glucaric Acid | 1 | 2017 | 2 | 0.140 |
Why?
| Ferric Compounds | 1 | 2017 | 17 | 0.140 |
Why?
| Drug Therapy, Combination | 2 | 2017 | 395 | 0.140 |
Why?
| Lung Neoplasms | 1 | 2024 | 636 | 0.140 |
Why?
| Myocytes, Cardiac | 1 | 2018 | 129 | 0.140 |
Why?
| beta Catenin | 2 | 2015 | 102 | 0.140 |
Why?
| M Phase Cell Cycle Checkpoints | 1 | 2017 | 5 | 0.140 |
Why?
| Mice, Knockout | 4 | 2023 | 879 | 0.140 |
Why?
| Hydroxamic Acids | 2 | 2014 | 38 | 0.140 |
Why?
| Aerobiosis | 1 | 2017 | 13 | 0.140 |
Why?
| Microfilament Proteins | 1 | 2017 | 43 | 0.130 |
Why?
| Onium Compounds | 1 | 2016 | 13 | 0.130 |
Why?
| Calcium-Binding Proteins | 1 | 2017 | 56 | 0.130 |
Why?
| Thyroid Hormones | 1 | 2017 | 22 | 0.130 |
Why?
| Organophosphorus Compounds | 1 | 2016 | 17 | 0.130 |
Why?
| Deoxyglucose | 1 | 2016 | 35 | 0.130 |
Why?
| Histone Deacetylase Inhibitors | 2 | 2014 | 58 | 0.130 |
Why?
| Survival Analysis | 6 | 2020 | 673 | 0.130 |
Why?
| Inhibitor of Apoptosis Proteins | 3 | 2015 | 21 | 0.130 |
Why?
| Gene Deletion | 2 | 2008 | 272 | 0.130 |
Why?
| Syndecans | 3 | 2006 | 37 | 0.130 |
Why?
| Pancreatic Neoplasms | 1 | 2019 | 216 | 0.130 |
Why?
| RNA Interference | 2 | 2015 | 181 | 0.130 |
Why?
| Cell Death | 1 | 2016 | 177 | 0.130 |
Why?
| Ribosomal Proteins | 1 | 2016 | 24 | 0.130 |
Why?
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2016 | 45 | 0.130 |
Why?
| Proto-Oncogene Proteins | 2 | 2009 | 151 | 0.120 |
Why?
| Proteoglycans | 3 | 2006 | 87 | 0.120 |
Why?
| Neoplasm Staging | 4 | 2025 | 772 | 0.120 |
Why?
| Muscle Proteins | 1 | 2018 | 321 | 0.120 |
Why?
| Oncolytic Virotherapy | 1 | 2015 | 21 | 0.120 |
Why?
| Macrophages | 2 | 2022 | 379 | 0.120 |
Why?
| Gene Dosage | 2 | 2013 | 78 | 0.120 |
Why?
| Cell Adhesion Molecules | 1 | 2015 | 86 | 0.120 |
Why?
| Calcium Channels | 1 | 2015 | 42 | 0.120 |
Why?
| Polysaccharides | 1 | 2015 | 57 | 0.120 |
Why?
| Receptors, Transferrin | 1 | 2015 | 16 | 0.120 |
Why?
| Core Binding Factor Alpha 1 Subunit | 1 | 2015 | 47 | 0.120 |
Why?
| Mitochondria, Heart | 1 | 2015 | 37 | 0.120 |
Why?
| Side-Population Cells | 1 | 2015 | 3 | 0.120 |
Why?
| Patient Selection | 2 | 2023 | 259 | 0.120 |
Why?
| Serine Endopeptidases | 2 | 2006 | 50 | 0.120 |
Why?
| Lentivirus | 1 | 2015 | 17 | 0.120 |
Why?
| Retinal Dehydrogenase | 1 | 2014 | 10 | 0.120 |
Why?
| Receptors, Cell Surface | 1 | 2015 | 118 | 0.120 |
Why?
| Adenine | 1 | 2015 | 31 | 0.120 |
Why?
| Transcription, Genetic | 3 | 2018 | 378 | 0.120 |
Why?
| Caspase 3 | 2 | 2022 | 95 | 0.120 |
Why?
| Serum | 1 | 2014 | 32 | 0.110 |
Why?
| Cell Lineage | 1 | 2014 | 85 | 0.110 |
Why?
| Proto-Oncogene Proteins c-kit | 1 | 2014 | 33 | 0.110 |
Why?
| Superoxide Dismutase | 1 | 2014 | 119 | 0.110 |
Why?
| Translocation, Genetic | 4 | 2021 | 265 | 0.110 |
Why?
| Tumor Burden | 3 | 2020 | 136 | 0.110 |
Why?
| Piperidines | 1 | 2015 | 97 | 0.110 |
Why?
| Stress, Physiological | 1 | 2015 | 183 | 0.110 |
Why?
| Cyclins | 3 | 2015 | 38 | 0.110 |
Why?
| Alkaline Phosphatase | 2 | 2011 | 94 | 0.110 |
Why?
| HLA Antigens | 1 | 2014 | 56 | 0.110 |
Why?
| Glycoproteins | 1 | 2014 | 122 | 0.110 |
Why?
| Repressor Proteins | 4 | 2015 | 155 | 0.110 |
Why?
| 11-beta-Hydroxysteroid Dehydrogenase Type 2 | 1 | 2013 | 12 | 0.110 |
Why?
| Leukemia, Plasma Cell | 1 | 2013 | 33 | 0.110 |
Why?
| Lactate Dehydrogenases | 1 | 2013 | 1 | 0.100 |
Why?
| Phenotype | 4 | 2009 | 789 | 0.100 |
Why?
| Genome, Human | 2 | 2021 | 121 | 0.100 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2013 | 61 | 0.100 |
Why?
| Follow-Up Studies | 5 | 2024 | 2279 | 0.100 |
Why?
| Dose-Response Relationship, Drug | 4 | 2020 | 1378 | 0.100 |
Why?
| Scavenger Receptors, Class A | 1 | 2013 | 39 | 0.100 |
Why?
| Leukemia | 1 | 2013 | 67 | 0.100 |
Why?
| bcl-X Protein | 1 | 2013 | 54 | 0.100 |
Why?
| Disease Models, Animal | 4 | 2020 | 1478 | 0.100 |
Why?
| Heart | 1 | 2015 | 345 | 0.100 |
Why?
| Heat-Shock Proteins | 1 | 2013 | 103 | 0.100 |
Why?
| RNA, Small Interfering | 2 | 2010 | 213 | 0.100 |
Why?
| RNA, Neoplasm | 3 | 2007 | 45 | 0.100 |
Why?
| Forkhead Transcription Factors | 2 | 2023 | 116 | 0.100 |
Why?
| Clinical Trials, Phase III as Topic | 2 | 2012 | 48 | 0.100 |
Why?
| Cysteine Proteinase Inhibitors | 1 | 2011 | 21 | 0.090 |
Why?
| Drug Screening Assays, Antitumor | 3 | 2020 | 136 | 0.090 |
Why?
| Activated Protein C Resistance | 1 | 2011 | 10 | 0.090 |
Why?
| Factor V | 1 | 2011 | 11 | 0.090 |
Why?
| Protein Isoforms | 2 | 2009 | 123 | 0.090 |
Why?
| Acetylcysteine | 1 | 2011 | 102 | 0.090 |
Why?
| Glucocorticoids | 1 | 2013 | 235 | 0.090 |
Why?
| Interferon Regulatory Factor-1 | 1 | 2010 | 14 | 0.090 |
Why?
| Cell Growth Processes | 1 | 2010 | 22 | 0.090 |
Why?
| HLA-A Antigens | 2 | 2007 | 11 | 0.090 |
Why?
| Cells, Cultured | 6 | 2015 | 1567 | 0.080 |
Why?
| Gene Silencing | 2 | 2007 | 118 | 0.080 |
Why?
| Alleles | 2 | 2021 | 276 | 0.080 |
Why?
| Mice, Inbred C57BL | 3 | 2021 | 1884 | 0.080 |
Why?
| Thrombosis | 1 | 2012 | 253 | 0.080 |
Why?
| K562 Cells | 3 | 2016 | 42 | 0.080 |
Why?
| Immunophenotyping | 5 | 2010 | 117 | 0.080 |
Why?
| Epigenesis, Genetic | 2 | 2023 | 406 | 0.080 |
Why?
| Microtubule-Associated Proteins | 1 | 2009 | 65 | 0.080 |
Why?
| Recombinant Proteins | 1 | 2010 | 483 | 0.080 |
Why?
| Bone Remodeling | 1 | 2010 | 155 | 0.080 |
Why?
| Chromosome Mapping | 2 | 2006 | 154 | 0.080 |
Why?
| HCT116 Cells | 2 | 2020 | 30 | 0.080 |
Why?
| Thromboembolism | 1 | 2009 | 52 | 0.080 |
Why?
| Lymphocyte Subsets | 1 | 2008 | 14 | 0.070 |
Why?
| Mutation | 3 | 2021 | 1347 | 0.070 |
Why?
| ras Proteins | 2 | 2020 | 64 | 0.070 |
Why?
| Angiogenesis Inhibitors | 1 | 2009 | 183 | 0.070 |
Why?
| Receptors, Immunologic | 1 | 2008 | 39 | 0.070 |
Why?
| Neoplasm Transplantation | 2 | 2020 | 87 | 0.070 |
Why?
| G2 Phase Cell Cycle Checkpoints | 2 | 2020 | 9 | 0.070 |
Why?
| Protein Tyrosine Phosphatases | 1 | 2007 | 15 | 0.070 |
Why?
| Adoptive Transfer | 1 | 2007 | 29 | 0.070 |
Why?
| Risk Assessment | 3 | 2025 | 1327 | 0.070 |
Why?
| Genes, abl | 1 | 2007 | 2 | 0.070 |
Why?
| Breast Neoplasms | 2 | 2007 | 1212 | 0.070 |
Why?
| Cross-Sectional Studies | 2 | 2023 | 1678 | 0.070 |
Why?
| HEK293 Cells | 2 | 2019 | 229 | 0.070 |
Why?
| Cancer Vaccines | 1 | 2007 | 78 | 0.070 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 2007 | 72 | 0.070 |
Why?
| Drug Evaluation, Preclinical | 2 | 2021 | 146 | 0.070 |
Why?
| Caspases | 1 | 2007 | 104 | 0.070 |
Why?
| Cyclin D | 1 | 2006 | 18 | 0.060 |
Why?
| Chromosome Banding | 1 | 2006 | 24 | 0.060 |
Why?
| Models, Genetic | 1 | 2006 | 169 | 0.060 |
Why?
| Proportional Hazards Models | 2 | 2024 | 443 | 0.060 |
Why?
| Palatine Tonsil | 2 | 2003 | 11 | 0.060 |
Why?
| DNA Damage | 1 | 2008 | 305 | 0.060 |
Why?
| Peptides | 1 | 2007 | 223 | 0.060 |
Why?
| Maf Transcription Factors, Large | 1 | 2005 | 1 | 0.060 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2007 | 179 | 0.060 |
Why?
| Data Interpretation, Statistical | 1 | 2006 | 164 | 0.060 |
Why?
| Doxorubicin | 2 | 2018 | 241 | 0.060 |
Why?
| Protein Kinases | 1 | 2005 | 72 | 0.060 |
Why?
| Cyclin D1 | 1 | 2005 | 57 | 0.060 |
Why?
| Antibody Formation | 1 | 2005 | 51 | 0.060 |
Why?
| Hydrogen Peroxide | 2 | 2017 | 120 | 0.060 |
Why?
| Protein Biosynthesis | 2 | 2003 | 258 | 0.060 |
Why?
| Neoplasm, Residual | 1 | 2025 | 173 | 0.060 |
Why?
| Papillomaviridae | 1 | 2005 | 105 | 0.060 |
Why?
| Base Sequence | 3 | 2015 | 640 | 0.060 |
Why?
| Cystadenocarcinoma, Serous | 1 | 2004 | 73 | 0.060 |
Why?
| Carcinoma, Papillary | 1 | 2004 | 51 | 0.060 |
Why?
| Transfection | 2 | 2020 | 357 | 0.060 |
Why?
| Consensus | 1 | 2025 | 181 | 0.060 |
Why?
| Mice, Inbred BALB C | 2 | 2019 | 312 | 0.060 |
Why?
| Drug Synergism | 2 | 2014 | 150 | 0.050 |
Why?
| Jurkat Cells | 2 | 2014 | 28 | 0.050 |
Why?
| Zebrafish Proteins | 1 | 2003 | 23 | 0.050 |
Why?
| Extracellular Matrix Proteins | 1 | 2004 | 69 | 0.050 |
Why?
| Adipogenesis | 1 | 2024 | 49 | 0.050 |
Why?
| Genetic Predisposition to Disease | 1 | 2007 | 528 | 0.050 |
Why?
| Glucose | 2 | 2016 | 355 | 0.050 |
Why?
| Ovariectomy | 1 | 2024 | 113 | 0.050 |
Why?
| Steroids | 1 | 2024 | 59 | 0.050 |
Why?
| PPAR gamma | 1 | 2024 | 72 | 0.050 |
Why?
| Sequence Analysis, RNA | 1 | 2024 | 100 | 0.050 |
Why?
| Integrin beta Chains | 1 | 2023 | 14 | 0.050 |
Why?
| Integrins | 1 | 2023 | 31 | 0.050 |
Why?
| Chromosomes, Human, Pair 13 | 1 | 2003 | 38 | 0.050 |
Why?
| Oxidative Phosphorylation | 1 | 2023 | 46 | 0.050 |
Why?
| Receptors, Fibroblast Growth Factor | 1 | 2002 | 8 | 0.050 |
Why?
| Cytogenetic Analysis | 1 | 2023 | 80 | 0.050 |
Why?
| Chromosomes, Human, Pair 4 | 1 | 2002 | 30 | 0.050 |
Why?
| Chromosomes, Human, Pair 14 | 1 | 2002 | 75 | 0.050 |
Why?
| Macrophage Activation | 1 | 2022 | 24 | 0.050 |
Why?
| Oncogene Proteins, Fusion | 1 | 2002 | 61 | 0.050 |
Why?
| Chromosome Deletion | 1 | 2023 | 142 | 0.050 |
Why?
| Computational Biology | 2 | 2020 | 212 | 0.050 |
Why?
| Geography | 1 | 2022 | 65 | 0.050 |
Why?
| Porphyromonas gingivalis | 1 | 2022 | 17 | 0.050 |
Why?
| Chromatin | 1 | 2023 | 139 | 0.050 |
Why?
| Uterine Cervical Neoplasms | 1 | 2005 | 299 | 0.050 |
Why?
| Diploidy | 3 | 2007 | 25 | 0.050 |
Why?
| DNA, Neoplasm | 1 | 2002 | 146 | 0.050 |
Why?
| Inflammasomes | 1 | 2022 | 66 | 0.050 |
Why?
| Models, Animal | 2 | 2015 | 234 | 0.050 |
Why?
| Mutation Rate | 1 | 2021 | 36 | 0.040 |
Why?
| DNA Primers | 2 | 2015 | 208 | 0.040 |
Why?
| Clone Cells | 1 | 2021 | 77 | 0.040 |
Why?
| Proteins | 1 | 2003 | 348 | 0.040 |
Why?
| Genes, Tumor Suppressor | 1 | 2021 | 74 | 0.040 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 69 | 0.040 |
Why?
| DNA Copy Number Variations | 1 | 2021 | 117 | 0.040 |
Why?
| Ovarian Neoplasms | 1 | 2004 | 459 | 0.040 |
Why?
| Cytokines | 3 | 2009 | 623 | 0.040 |
Why?
| Double-Blind Method | 2 | 2014 | 713 | 0.040 |
Why?
| 3' Untranslated Regions | 1 | 2020 | 55 | 0.040 |
Why?
| Wnt Signaling Pathway | 1 | 2021 | 94 | 0.040 |
Why?
| Immunohistochemistry | 3 | 2009 | 979 | 0.040 |
Why?
| Software | 1 | 2002 | 280 | 0.040 |
Why?
| Gene Knockout Techniques | 1 | 2019 | 46 | 0.040 |
Why?
| DNA | 1 | 2023 | 549 | 0.040 |
Why?
| Genetic Variation | 1 | 2020 | 230 | 0.040 |
Why?
| Crystallography, X-Ray | 1 | 2019 | 156 | 0.040 |
Why?
| Drug Discovery | 1 | 2020 | 93 | 0.040 |
Why?
| Protein Phosphatase 2 | 1 | 2019 | 4 | 0.040 |
Why?
| Multivariate Analysis | 1 | 2021 | 591 | 0.040 |
Why?
| G1 Phase | 1 | 2019 | 13 | 0.040 |
Why?
| Enzyme Activators | 1 | 2019 | 8 | 0.040 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 182 | 0.040 |
Why?
| Protein Conformation | 1 | 2019 | 176 | 0.040 |
Why?
| Immunotherapy | 1 | 2021 | 244 | 0.040 |
Why?
| Mice, Nude | 1 | 2019 | 265 | 0.040 |
Why?
| Antibody-Dependent Cell Cytotoxicity | 2 | 2009 | 12 | 0.040 |
Why?
| Structure-Activity Relationship | 1 | 2020 | 404 | 0.040 |
Why?
| Active Transport, Cell Nucleus | 1 | 2018 | 34 | 0.040 |
Why?
| Wnt Proteins | 2 | 2013 | 100 | 0.040 |
Why?
| Calpain | 1 | 2018 | 23 | 0.040 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2019 | 80 | 0.040 |
Why?
| Phosphorylation | 1 | 2020 | 528 | 0.040 |
Why?
| Drug Resistance | 1 | 2018 | 65 | 0.040 |
Why?
| DNA Methylation | 1 | 2023 | 592 | 0.040 |
Why?
| Autophagy | 1 | 2020 | 193 | 0.040 |
Why?
| Deferoxamine | 1 | 2017 | 9 | 0.040 |
Why?
| HT29 Cells | 1 | 2017 | 14 | 0.040 |
Why?
| Iron Chelating Agents | 1 | 2017 | 12 | 0.040 |
Why?
| Catalase | 1 | 2017 | 73 | 0.030 |
Why?
| Cell Cycle Checkpoints | 1 | 2017 | 32 | 0.030 |
Why?
| Cell Hypoxia | 1 | 2016 | 83 | 0.030 |
Why?
| Biological Transport | 1 | 2016 | 160 | 0.030 |
Why?
| Chronic Disease | 1 | 2019 | 586 | 0.030 |
Why?
| Endoplasmic Reticulum Stress | 1 | 2016 | 50 | 0.030 |
Why?
| Models, Statistical | 2 | 2008 | 230 | 0.030 |
Why?
| Drug Interactions | 1 | 2016 | 206 | 0.030 |
Why?
| Mice, Inbred ICR | 1 | 2016 | 25 | 0.030 |
Why?
| Cell Line | 2 | 2013 | 1030 | 0.030 |
Why?
| Transcriptional Activation | 1 | 2016 | 122 | 0.030 |
Why?
| Microscopy, Electron, Transmission | 1 | 2015 | 78 | 0.030 |
Why?
| Pharmacogenetics | 2 | 2006 | 50 | 0.030 |
Why?
| Vidarabine | 1 | 2015 | 8 | 0.030 |
Why?
| Reoviridae | 1 | 2015 | 25 | 0.030 |
Why?
| Mitoxantrone | 1 | 2015 | 9 | 0.030 |
Why?
| Myocardial Reperfusion | 1 | 2015 | 9 | 0.030 |
Why?
| Sarcoplasmic Reticulum | 1 | 2015 | 22 | 0.030 |
Why?
| Genes, Dominant | 1 | 2015 | 21 | 0.030 |
Why?
| Prostaglandin-Endoperoxide Synthases | 1 | 2015 | 25 | 0.030 |
Why?
| Antibodies, Monoclonal, Murine-Derived | 1 | 2015 | 46 | 0.030 |
Why?
| Diastole | 1 | 2015 | 70 | 0.030 |
Why?
| Vincristine | 1 | 2015 | 88 | 0.030 |
Why?
| Cytosol | 1 | 2015 | 80 | 0.030 |
Why?
| China | 1 | 2015 | 134 | 0.030 |
Why?
| Prednisone | 1 | 2015 | 102 | 0.030 |
Why?
| Cardiac Pacing, Artificial | 1 | 2015 | 34 | 0.030 |
Why?
| Ligands | 1 | 2015 | 206 | 0.030 |
Why?
| Vaccination | 2 | 2007 | 298 | 0.030 |
Why?
| Glutathione Peroxidase | 1 | 2014 | 23 | 0.030 |
Why?
| Cyclin B | 1 | 2014 | 4 | 0.030 |
Why?
| Microscopy, Fluorescence | 1 | 2015 | 160 | 0.030 |
Why?
| Molecular Targeted Therapy | 1 | 2016 | 133 | 0.030 |
Why?
| Disulfiram | 1 | 2014 | 13 | 0.030 |
Why?
| Cyclophosphamide | 1 | 2015 | 171 | 0.030 |
Why?
| CDC2 Protein Kinase | 1 | 2014 | 16 | 0.030 |
Why?
| Portraits as Topic | 1 | 2014 | 2 | 0.030 |
Why?
| Oxygen Consumption | 1 | 2015 | 198 | 0.030 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2014 | 39 | 0.030 |
Why?
| Antigens, Differentiation, T-Lymphocyte | 1 | 2013 | 11 | 0.030 |
Why?
| Chemotherapy, Adjuvant | 1 | 2014 | 124 | 0.030 |
Why?
| Lectins, C-Type | 1 | 2013 | 31 | 0.030 |
Why?
| Veratrum Alkaloids | 1 | 2013 | 5 | 0.030 |
Why?
| Multidrug Resistance-Associated Proteins | 1 | 2013 | 17 | 0.030 |
Why?
| Isoxazoles | 1 | 2013 | 15 | 0.030 |
Why?
| Calcium | 1 | 2015 | 376 | 0.030 |
Why?
| G1 Phase Cell Cycle Checkpoints | 1 | 2013 | 17 | 0.030 |
Why?
| Electrocardiography | 1 | 2015 | 268 | 0.030 |
Why?
| Glutathione | 1 | 2014 | 305 | 0.030 |
Why?
| Hedgehog Proteins | 1 | 2013 | 34 | 0.030 |
Why?
| Sulfones | 1 | 2013 | 25 | 0.030 |
Why?
| Gene Expression Regulation, Leukemic | 1 | 2013 | 32 | 0.030 |
Why?
| Itraconazole | 1 | 2013 | 38 | 0.030 |
Why?
| Peptide Library | 1 | 2013 | 16 | 0.030 |
Why?
| Receptors, Glucocorticoid | 1 | 2013 | 34 | 0.030 |
Why?
| Receptors, IgG | 1 | 2013 | 24 | 0.030 |
Why?
| Oxidants | 1 | 2013 | 51 | 0.030 |
Why?
| Azacitidine | 1 | 2013 | 39 | 0.030 |
Why?
| Heart Ventricles | 1 | 2015 | 267 | 0.030 |
Why?
| ADP-ribosyl Cyclase | 2 | 2003 | 4 | 0.030 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2013 | 94 | 0.030 |
Why?
| Hydrocortisone | 1 | 2013 | 111 | 0.030 |
Why?
| Epitopes | 1 | 2013 | 65 | 0.030 |
Why?
| MAP Kinase Signaling System | 1 | 2013 | 121 | 0.030 |
Why?
| Blood Pressure | 1 | 2015 | 537 | 0.020 |
Why?
| Histone Deacetylases | 1 | 2013 | 51 | 0.020 |
Why?
| Prospective Studies | 2 | 2010 | 2481 | 0.020 |
Why?
| Myocardium | 1 | 2015 | 453 | 0.020 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 129 | 0.020 |
Why?
| Radiation, Ionizing | 1 | 2013 | 101 | 0.020 |
Why?
| Osteoblasts | 2 | 2006 | 475 | 0.020 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2012 | 47 | 0.020 |
Why?
| Viper Venoms | 1 | 2011 | 7 | 0.020 |
Why?
| Protein C | 1 | 2011 | 20 | 0.020 |
Why?
| Risk | 1 | 2011 | 316 | 0.020 |
Why?
| Bone Density Conservation Agents | 1 | 2010 | 75 | 0.020 |
Why?
| Diphosphonates | 1 | 2010 | 92 | 0.020 |
Why?
| Databases as Topic | 1 | 2009 | 39 | 0.020 |
Why?
| Parathyroid Hormone | 1 | 2010 | 149 | 0.020 |
Why?
| Lymphocytes | 1 | 2010 | 153 | 0.020 |
Why?
| Cytoskeleton | 1 | 2008 | 39 | 0.020 |
Why?
| Genotype | 1 | 2009 | 566 | 0.020 |
Why?
| Twins | 1 | 2007 | 33 | 0.020 |
Why?
| STAT Transcription Factors | 1 | 2007 | 8 | 0.020 |
Why?
| Cytological Techniques | 1 | 2007 | 13 | 0.020 |
Why?
| NF-kappa B p52 Subunit | 1 | 2007 | 6 | 0.020 |
Why?
| NF-kappa B p50 Subunit | 1 | 2007 | 17 | 0.020 |
Why?
| I-kappa B Kinase | 1 | 2007 | 20 | 0.020 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2009 | 236 | 0.020 |
Why?
| Karyotyping | 1 | 2007 | 78 | 0.020 |
Why?
| T-Lymphocytes, Cytotoxic | 1 | 2007 | 66 | 0.020 |
Why?
| HLA-A2 Antigen | 1 | 2007 | 11 | 0.020 |
Why?
| Benzamides | 1 | 2007 | 50 | 0.020 |
Why?
| Antigen Presentation | 1 | 2007 | 26 | 0.020 |
Why?
| Remission Induction | 1 | 2007 | 218 | 0.020 |
Why?
| Polysaccharide-Lyases | 1 | 2007 | 7 | 0.020 |
Why?
| Leukocytes, Mononuclear | 1 | 2007 | 123 | 0.020 |
Why?
| Plasmids | 1 | 2007 | 163 | 0.020 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 235 | 0.020 |
Why?
| Enzyme Activation | 1 | 2007 | 270 | 0.020 |
Why?
| Tissue Culture Techniques | 1 | 2007 | 42 | 0.020 |
Why?
| Interferon-gamma | 1 | 2007 | 180 | 0.020 |
Why?
| Multigene Family | 1 | 2006 | 48 | 0.020 |
Why?
| Piperazines | 1 | 2007 | 118 | 0.020 |
Why?
| Neoplasms, Experimental | 1 | 2007 | 114 | 0.020 |
Why?
| Anticoagulants | 1 | 2009 | 270 | 0.020 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2006 | 53 | 0.020 |
Why?
| Diagnosis, Differential | 1 | 2010 | 1046 | 0.020 |
Why?
| Dendritic Cells | 1 | 2007 | 136 | 0.020 |
Why?
| Polymerase Chain Reaction | 1 | 2007 | 461 | 0.020 |
Why?
| Receptors, Estrogen | 1 | 2007 | 131 | 0.020 |
Why?
| Incidence | 1 | 2009 | 1062 | 0.020 |
Why?
| Gelatinases | 1 | 2006 | 32 | 0.020 |
Why?
| Chromosomes, Human | 1 | 2006 | 41 | 0.020 |
Why?
| Endopeptidases | 1 | 2006 | 66 | 0.020 |
Why?
| Rabbits | 1 | 2006 | 375 | 0.020 |
Why?
| Coculture Techniques | 1 | 2006 | 144 | 0.020 |
Why?
| Combined Modality Therapy | 1 | 2007 | 639 | 0.020 |
Why?
| Cyclin D3 | 1 | 2005 | 5 | 0.010 |
Why?
| Cyclin D2 | 1 | 2005 | 21 | 0.010 |
Why?
| Adipocytes | 1 | 2006 | 132 | 0.010 |
Why?
| Trisomy | 1 | 2005 | 35 | 0.010 |
Why?
| Oligonucleotide Probes | 1 | 2004 | 19 | 0.010 |
Why?
| Stem Cells | 1 | 2006 | 177 | 0.010 |
Why?
| Epithelium | 1 | 2004 | 65 | 0.010 |
Why?
| Molecular Sequence Data | 1 | 2006 | 778 | 0.010 |
Why?
| Endothelium, Vascular | 1 | 2006 | 246 | 0.010 |
Why?
| Ovary | 1 | 2004 | 107 | 0.010 |
Why?
| Endothelial Cells | 1 | 2006 | 262 | 0.010 |
Why?
| Bacterial Proteins | 1 | 2007 | 361 | 0.010 |
Why?
| Databases, Factual | 1 | 2007 | 706 | 0.010 |
Why?
| RNA, Complementary | 1 | 2003 | 2 | 0.010 |
Why?
| Autocrine Communication | 1 | 2003 | 7 | 0.010 |
Why?
| Paracrine Communication | 1 | 2003 | 12 | 0.010 |
Why?
| Metaphase | 1 | 2003 | 46 | 0.010 |
Why?
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2002 | 18 | 0.010 |
Why?
| Cell Separation | 1 | 2003 | 83 | 0.010 |
Why?
| NAD+ Nucleosidase | 1 | 2002 | 2 | 0.010 |
Why?
| Melanoma-Specific Antigens | 1 | 2002 | 3 | 0.010 |
Why?
| Biopsy | 1 | 2005 | 605 | 0.010 |
Why?
| Antigens, Differentiation | 1 | 2002 | 16 | 0.010 |
Why?
| Cell Communication | 1 | 2003 | 71 | 0.010 |
Why?
| Gene Expression Regulation, Developmental | 1 | 2003 | 137 | 0.010 |
Why?
| Cohort Studies | 1 | 2006 | 1542 | 0.010 |
Why?
| Immunoglobulins | 1 | 2002 | 76 | 0.010 |
Why?
| Database Management Systems | 1 | 2002 | 28 | 0.010 |
Why?
| Reproducibility of Results | 1 | 2005 | 1229 | 0.010 |
Why?
| Logistic Models | 1 | 2003 | 925 | 0.010 |
Why?
| Magnetic Resonance Imaging | 1 | 2003 | 1546 | 0.010 |
Why?
|
|
Zhan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|